DTC Print Ads: NEJM, Industry Critique FDA Guidance For Clarifying Risk Info
This article was originally published in The Pink Sheet Daily
Executive Summary
Article suggests that a Drug Facts box could specify the proportion of patients who benefitted from the drug in key trials and how many had adverse events; PhRMA calls for revision to regulations, preclearance regime.